US Approvals Analysis: Molecular Dx Innovations Make Waves In November
Executive Summary
Four novel molecular diagnostics, including two next-generation sequencing platforms, gained FDA approval in November, almost half of the nine novel-device approvals last month. The agency was also active with PMA supplement approvals and 510(k) clearances during the period.
You may also be interested in...
First Expedited NGS Test Breaks Through FDA Review
FDA has approved FoundationOne CDx, the first next-generation sequencing test to clear the agency's expedited access pathway as a breakthrough-designated diagnostic. The companion diagnostic also nabbed a positive national Medicare coverage propose simultaneously thanks to the FDA/CMS Parallel Review Program.
Neurostimulator Is First Device Marketed To Reduce Opioid Withdrawal Symptoms
FDA used its de novo pathway to clear Innovative Health Solution's NSS-2 Bridge – the first device for use in helping to reduce the symptoms of opioid withdrawal – as a class II device.
A New York Minute: US FDA Leverages State's Health Department To Expedite NGS Reviews
The agency authorized a next-generation sequencing tumor profiling system that leverages the New York State Department of Health to speed future clearances.